Spectrum reveals launch of new services in Vigo County
VIGO COUNTY, Ind. (WTWO/WAWV)— Spectrum announced the launch of its new Internet, Mobile, TV, and Voice Services to 2,300 homes and small businesses in Vigo County.
According to the news release, these new services will be aimed at the more rural parts of Vigo County. Spectrum secured a multi-year rural construction initiative with a more than $7 billion private investment from the company. This initiative is set to add an additional 100,000-plus miles of fiber-optic network infrastructure that will deliver internet access to more than 1.7 million people across the country.
'Spectrum is bringing gigabit broadband to unserved communities in Indiana and across America,' said Josh Moore, Area Vice President for Spectrum's Midwest South Management Area. 'Our investment is making it possible to deliver the high-value broadband, mobile, TV and voice services now available in Vigo County. We are providing residents and small businesses superior connectivity at highly competitive prices, backed by a team of skilled local technicians and 100% U.S.-based customer service.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
30 minutes ago
- Yahoo
Nearly 300 employees out of work after Johnsonville closes packing plant in far south suburbs
MOMENCE, Ill. — A packing plant in the far south suburbs has closed, putting nearly 300 employees out of work. The Momence Packing Company, located at 334 North Street in Momence, was shuttered as of Monday, a spokesperson for Johnsonville, the Wisconsin-based sausage manufacturer, has confirmed. Ground beef sold nationwide possibly contaminated with E. coli The Momence facility was built in 1962 and began producing Johnsonville products in 1995. According to Johnsonville, the closing impacts 274 employees, who were notified Monday and will receive continued pay and benefits for 60 days. 'We made the difficult decision after evaluating how best to optimize our operations network to address current and future growth,' the spokesperson said in a statement. 'The work from this facility will transition to three other production facilities in Wisconsin and Kansas.' Read more: Latest Chicago news and headlines Johnsonville said it plans to demolish the Momence facility by the end of this year. The company also says about 100 new jobs will be created between two of its Wisconsin plants by the third quarter of this year, 20 to 25 new jobs in Sheboygan Falls and 70 to 75 new jobs in Watertown. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
30 minutes ago
- Yahoo
USS Gettysburg to return to Naval Station Norfolk after near 8 month deployment
NORFOLK, Va. (WAVY) – Sailors aboard the USS Gettysburg are returning to Naval Station Norfolk Friday after a near eight-month deployment to the U.S. 5th and 6th Fleet areas of operations. The crew departed in Sept. 2024 as a part of the Harry S. Truman Carrier Strike Group, which consisted of the USS Harry S. Truman, USS Stout and USS Jason Dunham. While deployed, the strike group completed exercises with NATO Allies and combat operations in the Red Sea. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
